11838 Federal Register / Vol. 89, No. 32 / Thursday, February 15, 2024 / Notices 

the staff resources and functions to the 

DIS immediate office; abolished the 

DIO’s Implementation Branch, 

Infrastructure Engineering Branch, 

System Operations Branch, Network 

and Communications Operations 

Branch, Systems Monitoring and 

Response Branch, and Systems 

Monitoring and Response Branch; 

established the Network Services 

Branch, Systems Services Branch, and 

Operations Branch in DIS; realigned 

staff resources based on their roles and 

responsibilities; abolished the Delivery 

Management Support Staff (DMSS) 

within OTD immediate office; abolished 

the Application Management Services 

Staff, Medical Products Branch, OC/ 

CVM/CTP Branch, ORA/CFSAN/CVM 

Branch, Enterprise Applications Branch, 

Data Management and Operations 

Branch within OIMT/OTD/Division of 

Application Services (DAS); established 

the Regulatory Operations Branch, 

Scientific Operations Branch, and 

Business & Post-Market Branch within 

DAS; retitled the Office of Data, 

Analytics, and Research (ODAR), Data 

Staff to the Analytics Staff; retitled the 

ODAR Health Informatics Staff to the 

Informatics Staff; established the Data 

and Analytics Governance Staff and 

Data Strategy and Services Staff within 

ODAR; abolished the Knowledge 

Management Staff (KMS) within ODAR 

and realigned the staff resources and 

functions to the Office of Organizational 

Excellence, Division of Knowledge & 

Communications; established the 

Division of Cybersecurity Capabilities 

(DCC), Division of Risk & Compliance 

(DRC), Division of Cybersecurity 

Operations (DCO), and the Division of 

Counterintelligence & Insider Threat 

(DCIT) within the Office of Information 

Security (OIS); established the 

Vulnerability Management Branch and 

Identity Management Branch under 

OIS/DCC; established the Information 

System Security Branch and Risk 

Compliance and Audit Branch under 

OIS/DRMC; established the CIOCC 

Operations Branch and Network 

Security Branch under OIS/DCO; 

established the Program Staff within the 

OIS immediate office; realigned OIS 

staff resources and functions within OIS 

based on their roles and responsibilities. 

The Food and Drug Administration 

Office of the Commissioner’s Office of 

Digital Transformation is headed by the 

Chief Information Officer and has been 

restructured as follows: 

Office of Digital Transformation (DCAD) 

Office of Information Management and 

Technology (DCADA) 

Enterprise Architecture Staff (DCADA1) 

Office of Technology and Delivery 

(DCADAA) 

Division of Infrastructure Services 

(DCADAAA) 

Network Services Branch (DCADAAA1) 

Systems Services Branch (DCADAAA2) 

Operations Branch (DCADAAA3) 

Division of Application Services 

(DCADAAB) 

Regulatory Operations Branch 

(DCADAAB1) 

Scientific Operations Branch 

(DCADAAB2) 

Business and Post-Market Branch 

(DCADAAB3) 

Division of Engineering (DCADAAC) 

Engineering Branch (DCADAAC1) 

Implementation Branch (DCADAAC2) 

Application Branch (DCADAAC3) 

Database & Content Services Branch 

(DCADAAC4) 

Office of Customer Experience 

(DCADAB) 

Division of Collaboration Services 

(DCADABA) 

Division of Service Desk and Support 

(DCADABB) 

Division of Endpoint Management 

(DCADABC) 

Division of End User Services 

(DCADABD) 

Division of Employee Information 

(DCADABE) 

Office of Information Security (DCADB) 

Program Staff (DCADB1) 

Division of Cybersecurity Capabilities 

(DCADBA) 

Vulnerability Management Branch 

(DCADBA1) 

Identity Management Branch 

(DCADBA2) 

Division of Risk and Compliance 

(DCADBB) 

Information System Security Branch 

(DCADBB1) 

Risk Compliance and Audit Branch 

(DCADBB2) 

Division of Cybersecurity Operations 

(DCADBC) 

CIOCC Operations Branch (DCADBC1) 

Network Security Branch (DCADBC2) 

Division of Counterintelligence/Insider 

Threat (DCADBD) 

Office of Data, Analytics, and Research 

(DCADC) 

Analytics Staff (DCADC1) 

Informatics Staff (DCADC2) 

Data and Analytics Governance Staff 

(DCADC4) 

Data Strategy and Services Staff 

(DCADC5) 

Office of Enterprise Portfolio 

Management (DCADD) 

Division of Acquisition Innovation 

(DCADDA) 

Acquisitions Operations Branch 

(DCADDA1) 

Acquisitions Governance Branch 

(DCADDA2) 

IT Asset Management Branch 

(DCADDA3) 

Division of Technology Business 

Management (DCADDB) 

IT Governance Branch (DCADDB1) 

Business Intelligence Branch 

(DCADDB2) 

Division of Finance and Budget 

(DCADDC) 

Budget Formulation Branch (DCADDC1) 

Budget Execution Branch (DCADDC2) 

Office of Organizational Excellence 

(DCADE) 

Talent Strategy Staff (DCADE1) 

Executive Services Staff (DCADE2) 

Division of People and Culture 

(DCADEA) 

Employee Experience Branch 

(DCADEA1) 

Learning and Development Branch 

(DCADEA2) 

Division of Knowledge and 

Communications (DCADEB) 

Knowledge and Innovation Branch 

(DCADEB1) 

Communications and Outreach Branch 

(DCADEB2) 

II. Delegations of Authority 

Pending further delegation, directives, 

or orders by the Commissioner of Food 

and Drugs, all delegations and 

redelegations of authority made to 

officials and employees of affected 

organizational components will 

continue in them or their successors 

pending further redelegations, provided 

they are consistent with this 

reorganization. 

III. Electronic Access 

This reorganization is reflected in 

FDA’s Staff Manual Guide (SMG). 

Persons interested in seeing the 

complete Staff Manual Guide can find it 

on FDA’s website at: https://www.fda.

gov/AboutFDA/ReportsManualsForms/ 

StaffManualGuides/default.htm. 

Authority: 44 U.S.C. 3101. 

Xavier Becerra, 

Secretary of Health and Human Services. 

[FR Doc. 2024–02603 Filed 2–14–24; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Agency Information Collection 

Activities: Submission to OMB for 

Review and Approval; Public Comment 

Request; DATA 2000 Waiver Training 

Payment Program Application for 

Payment, OMB No. 0906–0061 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 32 / Thursday, February 15, 2024 / Notices 11839 

ACTION: Notice. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995, 

HRSA submitted an Information 

Collection Request (ICR) to the Office of 

Management and Budget (OMB) for 

review and approval. Comments 

submitted during the first public review 

of this ICR will be provided to OMB. 

OMB will accept further comments from 

the public during the review and 

approval period. OMB may act on 

HRSA’s ICR only after the 30-day 

comment period for this notice has 

closed. 

DATES: Comments on this ICR should be 

received no later than March 18, 2024. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under Review—Open for 

Public Comments’’ or by using the 

search function. 

FOR FURTHER INFORMATION CONTACT: To 

request a copy of the clearance requests 

submitted to OMB for review, email 

Joella Roland, the HRSA Information 

Collection Clearance Officer, at 

paperwork@hrsa.gov or call (301) 443– 

3983. 

SUPPLEMENTARY INFORMATION: 

Information Collection Request Title: 

DATA 2000 Waiver Training Payment 

Program Application for Payment, OMB 

No. 0906–0061—Revision. 

Abstract: The Substance Use— 

Disorder Prevention that Promotes 

Opioid Recovery and Treatment for 

Patients and Communities (SUPPORT) 

Act (Pub. L. 115–271), section 6083, 

amended the Social Security Act 

(subsections 1834(o)(3) and 1833(bb)), 

authorizing the Secretary of Health and 

Human Services (Secretary) to pay 

Federally Qualified Health Centers 

(FQHC) and Rural Health Clinics (RHC) 

for the average cost of training for 

purposes of receiving a DATA 2000 

waiver for their physicians and 

practitioners to furnish opioid use 

disorder treatment services. The 

SUPPORT Act made $6 million 

available to FQHCs and $2 million 

available to RHCs under the DATA 2000 

Waiver Training Payment Program. To 

receive payment, FQHCs and RHCs 

must submit an application in the 

manner specified by the Secretary. 

Authority to administer the DATA 2000 

program has been delegated to HRSA. 

Further information about the program 

can be found in the link below which 

provides guidance on the requirements 

of the DATA 2000 program and how 

qualified FQHCs and RHCs can apply to 

the program: https://help.hrsa.gov/ 

display/public/EHBSKBFG/DATA+

2000+Waiver+Training+Payment+

Program+FAQs. 

This purpose of this revision is to 

update the burden estimate for the RHC 

application process because the funding 

appropriated for FQHC DATA 2000 

payments has been fully expended. 

Therefore, no new applications for 

FQHC DATA 2000 payments can be 

accepted or approved. Only Centers for 

Medicare & Medicaid Services certified 

RHCs can apply for payments through 

the DATA 2000 program, and pursuant 

to the authorizing statute and 

subsequent legislation eliminating the 

DATA 2000 waiver requirement, such 

RHCs may only receive payments with 

respect to providers who first received 

their DATA 2000 Waiver between 

January 1, 2019, and December 29, 2022. 

Applicant entities must provide 

information identifying the submitting 

organization and the number of 

practitioners who have completed 

training and obtained a DATA 2000 

waiver. The form will also require the 

entity to include information regarding 

each claimed practitioner’s name, 

practitioner type (e.g., physician, 

physician assistant, nurse practitioner, 

certified nurse midwife, clinical nurse 

specialist, certified registered nurse, or 

anesthetist), National Provider Identifier 

number, Drug Enforcement 

Administration number, state license 

number, length of training, date the 

training was completed, date of waiver 

attainment, and DATA 2000 waiver 

number. Additionally, the form will 

require signature of an attestation 

statement certifying that: (1) each 

practitioner for which the entity is 

seeking payment under the application 

is employed by or working under 

contract for the applicant health facility; 

(2) it is the first time the entity is 

seeking payment on behalf of the listed 

practitioner(s); (3) the entity is eligible 

to seek payment under 42 U.S.C. 

1395m(o)(3) or 42 U.S.C. 1395l(bb); (4) 

each practitioner is furnishing opioid 

use disorder treatment services; and (5) 

the statements herein are true, complete, 

and accurate to the best of the 

applicant’s knowledge. 

A 60-day notice published in the 

Federal Register on December 4, 2023, 

vol. 88, No. 231; pp. 84149–50. There 

were no public comments. 

Need and Proposed Use of the 

Information: The Substance Use— 

Disorder Prevention that Promotes 

Opioid Recovery and Treatment for 

Patients and Communities Act requires 

RHCs to submit to the Secretary an 

application for payment at such time, in 

such manner, and containing such 

information as specified by the 

Secretary in order to receive a payment 

under section 6083. This form will 

allow RHCs to apply for such payments 

based on the average cost of training to 

obtain DATA 2000 waivers, as 

determined by the Secretary, for their 

physicians and practitioners to furnish 

opioid use disorder treatment services. 

The form will also provide HRSA with 

the requisite data to validate qualifying 

DATA 2000 waiver possessions for the 

purpose of ensuring accurate payments 

to RHCs. 

Likely Respondents: Only Centers for 

Medicare & Medicaid Services certified 

RHCs are eligible to apply. 

Burden Statement: Burden in this 

context means the time expended by 

persons to generate, maintain, retain, 

disclose, or provide the information 

requested. This includes the time 

needed to review instructions; to 

develop, acquire, install, and utilize 

technology and systems for the purpose 

of collecting, validating, and verifying 

information, processing and 

maintaining information, and disclosing 

and providing information; to train 

personnel and to be able to respond to 

a collection of information; to search 

data sources; to complete and review 

the collection of information; and to 

transmit or otherwise disclose the 

information. The total annual burden 

hours estimated for this ICR are 

summarized in the table below. 

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Total 

responses 

Average 

burden per 

response 

(in hours) 

Total 

burden 

hours 

DATA 2000 Waiver Training Payment Program Application for Payment 300 1 300 0.5 150.0 


khammond on DSKJM1Z7X2PROD with NOTICES

I I I 
11840 Federal Register / Vol. 89, No. 32 / Thursday, February 15, 2024 / Notices 

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Total 

responses 

Average 

burden per 

response 

(in hours) 

Total 

burden 

hours 

Total .................................................................................................... 300 1 300 .................... 150.0 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2024–03092 Filed 2–14–24; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Special 

Emphasis Panel: Cardiovascular 

Differentiation and Development. 

Date: March 6, 2024. 

Time: 9:30 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Sara Ahlgren, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, RM 4136, 

Bethesda, MD 20892, 301–435–0904, 

sara.ahlgren@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA: RM– 

23–015 Pilot Projects Enhancing Utility and 

Usage of Common Fund Data Sets Review. 

Date: March 13, 2024. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Katherine M. Malinda, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4140, 

MSC 7814, Bethesda, MD 20892, (301) 435– 

0912, malindakm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA Panel: 

Animal and Biological Material Resource 

Centers and Resource-Related Research 

Projects. 

Date: March 13, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Michael L. Bloom, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6187, 

MSC 7804, Bethesda, MD 20892, 301–451– 

0132, bloomm2@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Cell and Developmental Biology of 

Eye. 

Date: March 13, 2024. 

Time: 2:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Rass M. Shayiq, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2182, 

MSC 7818, Bethesda, MD 20892, (301) 435– 

2359, shayiqr@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Biomedical Sensing, Measurement 

and Instrumentation. 

Date: March 14–15, 2024. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Steven Anthony Ripp, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–3010, steven.ripp@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Neuroscience Assays, Diagnostics, 

Instrumentation, and Interventions. 

Date: March 14–15, 2024. 

Time: 8:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Aurea D. De Sousa, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5186, 

Bethesda, MD 20892, (301) 827–6829, 

aurea.desousa@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Biological Chemistry, Biophysics, 

and Assay Development. 

Date: March 14–15, 2024. 

Time: 9:00 a.m. to 7:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: John Harold Laity, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 402–8254, laityjh@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Health Services and Systems. 

Date: March 14–15, 2024. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Michael J. McQuestion, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3114, 

Bethesda, MD 20892, 301–480–1276, 

mike.mcquestion@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: February 12, 2024. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2024–03197 Filed 2–14–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 


khammond on DSKJM1Z7X2PROD with NOTICES

I I I